Toggle light / dark theme

First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides

Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by…

Programmable DNA insertion in native gut bacteria

In a new Science study, researchers describe MetaEdit, a strategy that enables targeted insertion of large DNA sequences into the genome of bacteria within the mouse gut environment.

Learn more in a new Science Perspective.


A gene-editing approach enables modification of bacteria within the mouse gut.

Amandine Maire and David Bikard Authors Info & Affiliations

Science

Vol 390, Issue 6774

The fate of pyruvate dictates cell growth by modulating cellular redox potential

This ‘fundamental’ study uncovers how directing pyruvate into mitochondria can shrink cells by shifting their metabolism away from building amino acids and proteins.


This fundamental work demonstrates that compartmentalized cellular metabolism is a dominant input into cell size control in a variety of mammalian cell types and in Drosophila. The authors show that increased pyruvate import into the mitochondria in liver-like cells and in primary hepatocytes drives gluconeogenesis but reduces cellular amino acid production, suppressing protein synthesis. The evidence supporting the conclusions is compelling, with a variety of genetic and pharmacologic assays rigorously testing each step of the proposed mechanism. This work will be of interest to cell biologists, physiologists, and researchers interested in cell metabolism, and is significant because stem cells and many cancers exhibit metabolic rewiring of pyruvate metabolism.

New Dementia Pill Clears First Major Safety Hurdle, Trial Reports

A new pill for treating dementia is delivering promising “topline” results in early-stage clinical trials, according to a recent press release by its makers.

The treatment, called VES001 after its developer Vesper Bio, is designed to tackle frontotemporal dementia (FTD) – the most common type of dementia in the under-60s.

In a two-part preliminary safety trial at two medical centres in the Netherlands and the UK, VES001 was given to people showing no signs of FTD, including six volunteers with an increased genetic risk for the condition.

/* */